PT-141 (10 mg vial)

Protocol Overview

Concise summary of the regimen.

Dosing & Reconstitution

Injections are given subcutaneously into the abdomen or thigh, either once daily on the gradual approach or as a single dose before anticipated activity on the FDA-approved on-demand regimen, which caps use at 8 doses per month. The subcutaneous route provides approximately 100% bioavailability and is better tolerated than intranasal delivery. Daily protocols at 2.5 mg have been studied in obese women for appetite and weight reduction, which suggests daily use can be tolerated. The gradual schedule is deliberately conservative: it starts at 500 mcg, well below the 1.75 mg on-demand dose, steps up after week 8, and steps up again after week 12. Sites are rotated systematically across the abdomen and thighs on different days to avoid lipodystrophy or irritation.

Results Timeline

Sequence described in the research record. Individual response varies.

• Weeks 1 to 8: 500 mcg daily, which is 5 units at 10 mg/mL, an entry phase held well below the FDA on-demand dose.
• Weeks 9 to 12: the daily dose doubles to 1,000 mcg, which is 10 units (0.10 mL).
• Weeks 13 to 16: an optional extension at 1,500 mcg daily, which is 15 units (0.15 mL), for protocols continuing past 12 weeks.
• Nausea, when it appears, is most common early and tends to be transient; flushing and headache may show up in the same window.
• Skin darkening from peripheral MC1R activation can develop over a longer course of repeated use and is generally reversible.

Reconstitution Steps

1. Draw 1.0 mL bacteriostatic water with a sterile syringe.
2. Inject slowly down the vial wall; avoid foaming.
3. Gently swirl until dissolved (do not shake).
4. Label with date and concentration; refrigerate at 2 to 8 °C, protected from light. At 10 mg/mL, 1 unit = 0.01 mL » 100 mcg on a U-100 insulin syringe, so 500 mcg = 5 units, 1,000 mcg = 10 units (0.10 mL), 1,500 mcg = 15 units (0.15 mL), and the 1.75 mg on-demand dose = 17.5 units (0.175 mL).

Storage Instructions

Proper storage preserves peptide quality.

• Lyophilized: store at minus 20 °C in dry, dark conditions and minimize moisture exposure.
• Reconstituted: refrigerate at 2 to 8 °C, use within approximately 30 days, and avoid repeated freeze-thaw.

• Allow vials to reach room temperature before opening to reduce condensation uptake.
• At 1.0 mL per vial the solution is concentrated: a 10 mg vial covers 20 days at 500 mcg daily but under 7 days at 1,500 mcg daily, so reconstitution is timed to finish each vial inside the 30 day window.

Supplies Needed

The figures below are based on the gradual once-daily approach over 8 to 16 weeks, starting at 500 mcg per day (3.5 mg per week) and titrating to 1,500 mcg per day (10.5 mg per week).

Peptide Vials (PT-141, 10 mg vial):

• Eight weeks totals about 28 mg, which is about 3 vials of 10 mg; 12 weeks totals about 56 mg, about 6 vials; and 16 weeks totals about 98 mg, about 10 vials.

Insulin Syringes (U-100):

• Per week: 7 U-100 insulin syringes, one per day.
• Full cycle: 56 syringes over 8 weeks, 84 over 12 weeks, and 112 over 16 weeks.

Bacteriostatic Water (10 mL bottles):

• Each 10 mg vial takes 1.0 mL, so a single 10 mL bottle covers 10 vials, which is enough for the full 16 week cycle.

Alcohol Swabs:

• Per injection: 2 swabs, one for the vial stopper and one for the site, which is 14 per week.
• Full cycle: 112 swabs over 8 weeks, 168 over 12 weeks, and 224 over 16 weeks, so two to three boxes of 100.

Important Notes

Practical considerations for consistency and safety.

• Use a new sterile U-100 insulin syringe (27 to 30G, 5/8 inch needle) for each injection and dispose of it in a sharps container.
• Rotate injection sites across the abdomen and thighs on different days to avoid lipodystrophy or irritation.
• Inject slowly and wait a few seconds before withdrawing the needle.
• Nausea is the most common side effect and tends to be transient; flushing and headache may also occur.
• Transient blood pressure increases have been reported, so the compound is not recommended alongside uncontrolled hypertension or cardiovascular disease. Recording the daily dose and the site used keeps rotation and tolerability easy to track.
• Regulatory Note: bremelanotide is FDA-approved as Vyleesi, cleared in 2019 for hypoactive sexual desire disorder in premenopausal women. Research-grade vials are not the approved product and are supplied for research use only, not for human consumption.

How This Works

Bremelanotide is a synthetic analog of alpha-melanocyte-stimulating hormone that acts as a non-selective melanocortin receptor agonist, predominantly targeting MC3R and MC4R. In the central nervous system, MC4R activation enhances dopamine release in key brain reward and arousal regions including the nucleus accumbens and medial preoptic area, which increases sexual motivation and desire. Unlike PDE5 inhibitors, bremelanotide does not directly affect the nitric oxide pathway; in men, its erectogenic effect is secondary to this central mechanism stimulating nitric oxide production in penile tissue. Peripheral MC1R agonism accounts for side effects such as transient blood pressure elevation and skin hyperpigmentation (tanning).

Benefits & Side Effects

Observations from the published record.

• Clinical trials in premenopausal women with HSDD demonstrated significant improvements in sexual desire scores (FSFI-Desire) and reduced distress (FSDS-DAO) versus placebo.
• Early studies also suggest potential benefit in men, with intranasal PT-141 improving erectile responses, alongside increased arousal measures in women.
• Adverse effects are usually mild and transient, most commonly nausea (about 40%), flushing, headache, and injection-site reactions.
• Transient blood pressure increases have been reported; the compound is not recommended for individuals with uncontrolled hypertension or cardiovascular disease.
• Skin darkening (hyperpigmentation) may occur with repeated use due to peripheral MC1R activation and is generally reversible.

Lifestyle Factors

Complementary strategies for best outcomes.

• Maintain a balanced diet and regular exercise routine to support overall hormonal health.
• Prioritize sleep quality, as poor sleep can negatively affect libido and hormonal balance.
• Manage stress through mindfulness, therapy, or relaxation techniques.
• Limit alcohol consumption, which may dampen the effects of melanocortin receptor activation.

Injection Technique

General subcutaneous guidance from clinical best-practice resources.

1. Clean the vial stopper and skin with alcohol; allow to dry.
2. Pinch a skinfold; insert the needle at 45 to 90 degrees into subcutaneous tissue.
3. Do not aspirate for subcutaneous injections; inject slowly and steadily.
4. Wait 5 to 10 seconds before withdrawing; dispose of syringe in sharps container.
5. Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy.

References

Source citations for further reading.

1. Vyleesi (bremelanotide) prescribing information; approved 2019 for HSDD (FDA).
2. Bremelanotide for treatment of female hypoactive sexual desire: mechanism, trials, and safety review (PMC, 2022).
3. Bremelanotide (subcutaneous route): side effects, dosage, and precautions (Mayo Clinic).
4. Kingsberg SA et al. Bremelanotide for HSDD: two randomized phase 3 trials (RECONNECT, Obstet Gynecol, 2019).